Dose escalation with repeated intrathecal injections of 131I-labelled MAbs for the treatment of central nervous system malignancies.

We have previously demonstrated a 33% response rate in patients with primitive neurectodermal tumours after the direct injection of 131I-monoclonal antibodies (MAbs) into the cerebrospinal fluid (CSF). Dose-limiting toxicity is myelosuppression due to the passage of the radioimmunoconjugate from the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kemshead, J. T., Hopkins, K., Pizer, B., Papanastassiou, V., Coakham, H., Bullimore, J., Chandler, C.
Format:	Artigo
Language:	Inglês
Published:	Nature Publishing Group 1998
Subjects:	Research Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC2150406/ https://ncbi.nlm.nih.gov/pubmed/9649153
Tags:	Add Tag No Tags, Be the first to tag this record!

Dose escalation with repeated intrathecal injections of 131I-labelled MAbs for the treatment of central nervous system malignancies.

Similar Items